1. Home
  2. FGBI vs AGEN Comparison

FGBI vs AGEN Comparison

Compare FGBI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo First Guaranty Bancshares Inc.

FGBI

First Guaranty Bancshares Inc.

HOLD

Current Price

$9.91

Market Cap

151.6M

Sector

Finance

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$6.04

Market Cap

147.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FGBI
AGEN
Founded
1934
1994
Country
United States
United States
Employees
346
N/A
Industry
Savings Institutions
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
151.6M
147.4M
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
FGBI
AGEN
Price
$9.91
$6.04
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
67.7K
906.5K
Earning Date
04-27-2026
05-12-2026
Dividend Yield
0.44%
N/A
EPS Growth
N/A
100.00
EPS
N/A
1.02
Revenue
N/A
$42,877,086.00
Revenue This Year
$567.70
$107.63
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$3.28
Revenue Growth
N/A
89.95
52 Week Low
$4.31
$2.71
52 Week High
$11.02
$7.00

Technical Indicators

Market Signals
Indicator
FGBI
AGEN
Relative Strength Index (RSI) 48.62 83.67
Support Level $9.42 $2.96
Resistance Level $10.03 N/A
Average True Range (ATR) 0.55 0.49
MACD -0.08 0.22
Stochastic Oscillator 25.88 58.29

Price Performance

Historical Comparison
FGBI
AGEN

About FGBI First Guaranty Bancshares Inc.

First Guaranty Bancshares Inc provides personalized commercial banking services to its customers in Louisiana, through several banking facilities. The principal business activity of the company includes attracting deposits and investing it together with funds generated from operations and borrowings insecurities and in lending activities to serve the credit needs of its customer base. The company offers commercial real estate loans, commercial and industrial loans, construction and land development loans, agricultural and farmland loans, and to a lesser extent, consumer and multifamily loans.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: